The stock, currently trading at ₹172.10, has declined 12.73% over the past year, significantly underperforming the hospital sector's 20.18% gain by 32.91 percentage points. Despite the headline profit figure, operating margins contracted sharply to 10.21% in Q4 FY26 from 14.58% in Q2 FY26, highlighting deteriorating core business performance.
The quarter's financial performance reveals a troubling disconnect between reported profits and operational reality. Whilst net sales grew a modest 5.63% quarter-on-quarter to ₹287.45 crores, the company posted a negative tax rate of -92.09%, indicating a tax reversal of ₹8.85 crores that artificially inflated bottom-line figures. Without this accounting benefit, the underlying profit before tax stood at just ₹9.61 crores, barely improving from ₹9.23 crores in the previous quarter.
| Metric | Mar'26 | Dec'25 | Sep'25 | Jun'25 | Mar'25 |
|---|---|---|---|---|---|
| Net Sales (₹ Cr) | 287.45 | 272.13 | 285.43 | 296.43 | 264.89 |
| QoQ Growth | +5.63% | -4.66% | -3.71% | +11.91% | — |
| YoY Growth | +8.52% | -1.27% | +6.69% | — | — |
| Operating Margin (%) | 10.21% | 11.12% | 14.58% | 14.01% | 7.87% |
| PAT (₹ Cr) | 18.32 | 1.77 | 8.39 | 8.92 | -11.02 |
| QoQ Growth | +935.03% | -78.90% | -5.94% | -180.94% | — |
| PAT Margin (%) | 6.42% | 0.47% | 2.55% | 2.59% | -4.60% |
Financial Performance: Margin Compression Signals Operational Stress
A detailed examination of Shalby's quarterly performance reveals concerning trends beneath the surface-level profit growth. Operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI) declined to ₹29.36 crores in Q4 FY26 from ₹41.61 crores in Q2 FY26, representing a 29.44% sequential drop over two quarters. This deterioration translated into operating margins compressing from 14.58% in September 2025 to just 10.21% by March 2026—a decline of 437 basis points.
The margin pressure stems from multiple sources. Employee costs rose to ₹49.56 crores in Q4 FY26, up 5.41% sequentially, outpacing the 5.63% revenue growth and indicating diminishing labour productivity. Interest expenses, whilst moderating slightly to ₹9.34 crores from ₹10.64 crores in Q3 FY26, remain elevated due to the company's debt burden. Depreciation charges climbed to ₹18.49 crores, the highest in recent quarters, reflecting the capital-intensive nature of hospital expansion.
On a year-on-year basis, whilst revenue grew 8.52% in Q4 FY26 compared to Q4 FY25, the operating margin expansion from 7.87% to 10.21% appears modest given the low base effect from the prior year's loss-making quarter. More troublingly, the consolidated net profit of ₹18.32 crores in Q4 FY26 compares unfavourably to the loss of ₹11.02 crores in Q4 FY25, but this recovery is almost entirely attributable to the tax reversal rather than sustainable operational improvements.
Earnings Quality Concern: Non-Operating Income Dependence
A critical red flag emerges from the company's reliance on non-operating income. In Q4 FY26, other income of ₹8.08 crores constituted 84.08% of profit before tax (PBT), indicating that core operations contributed minimally to profitability. This heavy dependence on non-core income streams—likely comprising interest on deposits, dividend income, and other treasury operations—raises serious questions about the sustainability of reported earnings.
The Capital Efficiency Crisis: ROE Collapses to Near-Zero Levels
Perhaps the most alarming metric for long-term investors is Shalby's return on equity (ROE), which has plummeted to a dismal 0.45% as of March 2026. This represents one of the weakest capital efficiency ratios in the hospital sector and indicates that the company is generating virtually no returns on shareholder capital. For context, higher ROE values signify better capital efficiency and profitability—a principle that places Shalby at a severe disadvantage compared to peers.
The five-year average ROE of 5.51% is itself underwhelming, but the latest quarterly figure of 0.45% signals a dramatic deterioration in the company's ability to generate profits from equity capital. This weakness stems from a combination of factors: compressed operating margins, elevated debt servicing costs, and substantial depreciation charges that erode net profitability. With shareholder funds of ₹992.19 crores as of March 2025, the company's inability to generate meaningful returns raises fundamental questions about management's capital allocation decisions.
Return on capital employed (ROCE) tells a similarly troubling story, declining to 5.00% in the latest period from an already weak five-year average of 8.10%. This metric, which measures returns generated on all capital employed in the business (both equity and debt), suggests that Shalby's expansion strategy has not translated into proportionate profit growth. The company's sales to capital employed ratio of 0.68x indicates that it requires ₹1.47 of capital to generate ₹1 of sales—a relatively capital-intensive business model that demands high operational efficiency to justify returns.
Balance Sheet Strain: Debt Metrics Deteriorate
Shalby's balance sheet reveals mounting leverage concerns. Long-term debt increased to ₹136.67 crores as of March 2025 from ₹67.42 crores in March 2023, whilst current liabilities surged to ₹455.32 crores from ₹194.38 crores over the same period. The debt-to-equity ratio climbed to 0.59 times in the latest half-year, the highest in recent periods, indicating growing financial strain. Whilst the debt-to-EBITDA ratio of 1.94x remains within acceptable limits, the trend is deteriorating as EBITDA growth fails to keep pace with debt accumulation.
Cash Flow Concerns: Operations Turn Negative
A critical warning signal emerges from Shalby's cash flow statement for FY25. Cash flow from operations turned negative at ₹4.00 crores, a sharp reversal from the positive ₹19.00 crores generated in FY24. This deterioration stems primarily from adverse working capital movements, with ₹130.00 crores locked up in working capital during FY25 compared to ₹140.00 crores in the prior year. The negative operating cash flow, combined with profit before tax of ₹55.00 crores, suggests that accounting profits are not translating into actual cash generation—a red flag for earnings quality.
The company's working capital management has deteriorated significantly, with the inventory turnover ratio falling to 3.03 times in the latest half-year, the lowest in recent periods. The debtors turnover ratio similarly declined to 5.00 times, indicating slower collection cycles and potentially stretched receivables. These operational inefficiencies tie up capital that could otherwise be deployed for growth or debt reduction, further constraining financial flexibility.
| Cash Flow Metric | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Profit Before Tax (₹ Cr) | 55.00 | 128.00 | 102.00 | 79.00 |
| Changes in Working Capital (₹ Cr) | -130.00 | -140.00 | -45.00 | -90.00 |
| Operating Cash Flow (₹ Cr) | -4.00 | 19.00 | 67.00 | 18.00 |
| Investing Cash Flow (₹ Cr) | -35.00 | 146.00 | -61.00 | -60.00 |
| Financing Cash Flow (₹ Cr) | 47.00 | -150.00 | -50.00 | 90.00 |
Peer Comparison: Valuation Premium Unjustified by Fundamentals
When benchmarked against hospital sector peers, Shalby's valuation appears significantly stretched relative to its operational performance. The company trades at a price-to-earnings ratio of 226.87x, nearly 7 times the industry average P/E of approximately 33x. This extreme valuation multiple is particularly difficult to justify given Shalby's ROE of just 5.51%, which ranks at the bottom of its peer group.
| Company | P/E (TTM) | P/BV | ROE (%) | Debt/Equity | Div Yield |
|---|---|---|---|---|---|
| Shalby | 226.87 | 1.82 | 5.51% | 0.43 | NA |
| Yatharth Hospital | 44.53 | 4.40 | 9.01% | 0.00 | NA |
| Kovai Medical | 24.01 | 4.93 | 19.55% | 0.08 | 0.19% |
| Artemis Medicare | 41.34 | 4.68 | 10.12% | 0.06 | 0.14% |
| Indraprastha Medical | 19.58 | 5.46 | 24.88% | -0.65 | 1.15% |
| Dr Agarwal's Eye | 35.23 | 7.13 | 27.84% | 0.67 | 0.13% |
Whilst Shalby's price-to-book value of 1.82x appears reasonable compared to the peer average of approximately 5.3x, this discount reflects the market's recognition of the company's weak return profile. Investors typically assign lower P/BV multiples to companies with poor capital efficiency, as book value becomes less relevant when a company cannot generate adequate returns on that capital. The comparison with Indraprastha Medical (ROE of 24.88%, P/E of 19.58x) and Dr Agarwal's Eye (ROE of 27.84%, P/E of 35.23x) starkly illustrates how Shalby's fundamentals fail to justify its valuation premium.
Valuation Analysis: Expensive Despite Weak Fundamentals
Despite the company's operational challenges and weak return metrics, Shalby's proprietary valuation assessment indicates a "Very Attractive" grade as of May 2026. This rating appears to be driven primarily by the stock's 37.30% decline from its 52-week high of ₹274.50, rather than improvements in fundamental value. At the current price of ₹172.10, the stock trades at an enterprise value-to-EBITDA multiple of 16.81x and EV-to-sales of 2.02x.
However, these valuation metrics must be viewed in context. The P/E ratio of 226.87x is unsustainably high and reflects the company's minimal net profit of just ₹1.00 crore for the full year FY25 (before the Q4 FY26 tax reversal). The EV-to-EBIT multiple of 33.93x similarly appears elevated given the company's deteriorating operating margins. More concerning is the EV-to-capital employed ratio of 1.58x, which, when paired with a ROCE of just 5.00%, suggests the market is valuing the company's assets at a premium despite their inability to generate adequate returns.
Shareholding: Promoter Stability Amidst Institutional Apathy
Shalby's shareholding pattern reveals a concentrated promoter base with minimal institutional participation. Promoter holding has remained stable at 74.33% over the past three quarters, with the Shah Family Trust (through Dr Vikram Shah) and Zodiac Mediquip Limited holding 34.79% and 29.21% respectively. The absence of pledged shares is a positive indicator, suggesting promoters are not under financial stress.
| Shareholder Category | Mar'26 | Dec'25 | Sep'25 | Jun'25 | QoQ Change |
|---|---|---|---|---|---|
| Promoter Holding | 74.33% | 74.33% | 74.33% | 74.27% | 0.00% |
| FII Holding | 4.36% | 4.47% | 4.64% | 5.20% | -0.11% |
| Mutual Fund | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Insurance | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other DII | 0.25% | 0.19% | 0.19% | 0.19% | +0.06% |
| Non-Institutional | 21.07% | 21.01% | 20.84% | 20.33% | +0.06% |
However, the near-complete absence of institutional investors is a significant red flag. Foreign institutional investors (FIIs) have been gradually reducing their stake, declining from 5.20% in June 2025 to 4.36% by March 2026. More tellingly, mutual funds and insurance companies have zero holdings in the stock, indicating a lack of conviction from sophisticated institutional investors who typically conduct rigorous due diligence. The total institutional holding of just 4.61% places Shalby among the least favoured stocks in the hospital sector and suggests that professional investors harbour serious concerns about the company's prospects.
Stock Performance: Severe Underperformance Across All Timeframes
Shalby's stock price performance has been dismal across virtually all timeframes, with the company significantly underperforming both the broader market and its hospital sector peers. Over the past year, the stock has declined 12.73%, generating negative alpha of -5.79% versus the Sensex's -6.94% return. More concerning is the two-year performance, with the stock plummeting 36.54% whilst the Sensex gained 1.97%—a staggering underperformance of 38.51 percentage points.
| Period | Stock Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | +0.94% | +0.73% | +0.21% |
| 1 Month | +6.50% | -1.97% | +8.47% |
| 3 Month | +11.10% | -6.54% | +17.64% |
| 6 Month | -17.38% | -11.36% | -6.02% |
| YTD | -15.37% | -10.86% | -4.51% |
| 1 Year | -12.73% | -6.94% | -5.79% |
| 2 Years | -36.54% | +1.97% | -38.51% |
| 3 Years | +25.71% | +20.88% | +4.83% |
The stock's volatility of 40.31% over the past year, combined with negative returns, results in a negative risk-adjusted return of -0.32 and classifies it as "HIGH RISK LOW RETURN"—the worst possible risk-return profile for investors. The stock's beta of 1.36 indicates it is significantly more volatile than the broader market, amplifying losses during downturns without providing commensurate upside during recoveries.
From a technical perspective, the stock currently trades in a "Mildly Bearish" trend, having changed from bearish on April 10, 2026, at ₹153.55. The stock is trading below all key moving averages, including the 200-day moving average of ₹192.32, indicating sustained selling pressure. Immediate resistance lies at the 20-day moving average of ₹165.19, whilst support rests at the 52-week low of ₹125.70. The stock's distance of 37.30% below its 52-week high of ₹274.50 underscores the severity of the price correction.
Investment Thesis: Quality Concerns Outweigh Valuation Appeal
Shalby's investment case presents a complex picture where superficial valuation attractiveness is undermined by fundamental operational weaknesses. The company's proprietary Mojo score of 51 out of 100 results in a "HOLD" rating, reflecting mixed signals across key investment parameters. Whilst the valuation grade registers as "Very Attractive" and the financial trend for Q4 FY26 is classified as "Positive," these factors are offset by "Average" quality assessment and "Mildly Bearish" technical indicators.
Key Strengths & Risk Factors
KEY STRENGTHS ✓
- Strong Long-Term Growth: Net sales have grown at an annual rate of 23.17% and operating profit at 25.38% over five years, demonstrating the company's ability to scale operations.
- Manageable Debt Levels: Low debt-to-EBITDA ratio of 1.94 times indicates the company has adequate ability to service its debt obligations from operating cash flows.
- Zero Promoter Pledging: The absence of pledged shares suggests promoters are not under financial stress and remain committed to the business.
- Stable Promoter Base: Promoter holding of 74.33% provides management stability and alignment of interests with minority shareholders.
- Positive Financial Trend (Q4): The latest quarter shows positive momentum, though heavily influenced by one-time tax benefits.
- Sector Tailwinds: India's healthcare sector offers long-term structural growth opportunities driven by rising income levels and health awareness.
KEY CONCERNS ⚠️
- Collapsed ROE: Return on equity of just 0.45% indicates the company is generating virtually no returns on shareholder capital—a critical red flag.
- Margin Compression: Operating margins declined from 14.58% in Q2 FY26 to 10.21% in Q4 FY26, signalling deteriorating pricing power or cost control issues.
- Earnings Quality Issues: Q4 FY26 profit driven by tax reversal rather than operational improvements; non-operating income constitutes 84.08% of PBT.
- Negative Operating Cash Flow: FY25 operating cash flow turned negative at ₹4.00 crores, indicating accounting profits are not converting to cash.
- Deteriorating Working Capital: Inventory turnover and debtor turnover ratios at multi-quarter lows, indicating operational inefficiencies.
- Institutional Exodus: Zero mutual fund and insurance holdings; FII stake declining from 5.20% to 4.36% signals lack of professional investor confidence.
- Extreme Valuation Multiple: P/E of 226.87x is unsustainable and reflects minimal net profit base rather than genuine value.
Outlook: What to Watch in Coming Quarters
POSITIVE CATALYSTS 📈
- Margin Recovery: Sustained improvement in operating margins back towards 14-15% levels would signal operational turnaround.
- Cash Flow Normalisation: Return to positive operating cash flow would validate earnings quality and ease working capital concerns.
- ROE Improvement: Any meaningful uptick in return on equity towards peer levels (10%+) would justify current valuations.
- Institutional Interest: Entry of mutual funds or increase in FII holdings would signal improved confidence.
- Debt Reduction: Deleveraging the balance sheet would reduce financial risk and improve return metrics.
RED FLAGS 🚩
- Further Margin Erosion: Operating margins falling below 10% would indicate structural profitability challenges.
- Continued Cash Burn: Persistent negative operating cash flows would necessitate additional debt or equity dilution.
- Working Capital Deterioration: Further decline in inventory or debtor turnover ratios would strain liquidity.
- Institutional Selling: Additional reduction in FII holdings or insider selling would signal waning confidence.
- Debt Covenant Concerns: Rising debt-to-equity ratio beyond 0.6x could trigger covenant issues or refinancing challenges.
For the coming quarters, investors should closely monitor whether the company can sustain profitability without reliance on one-time tax benefits or non-operating income. The true test will be whether operating margins can stabilise above 12% and whether the company can generate positive operating cash flows consistently. Any further deterioration in return metrics or working capital efficiency would warrant a reassessment of the investment case.
The Verdict: Operational Weakness Outweighs Valuation Discount
Score: 51/100
For Fresh Investors: Avoid initiating positions. The combination of collapsed ROE (0.45%), margin compression, negative operating cash flows, and heavy reliance on non-operating income for profitability presents unacceptable risks. Whilst the stock has corrected 37% from its peak, this appears to be a value trap rather than a genuine opportunity. The extreme P/E multiple of 226.87x is unsustainable and offers no margin of safety.
For Existing Holders: Hold with caution and monitor closely. Set a stop loss at ₹155 (10% below current levels). If the company can demonstrate sustained margin recovery above 12%, positive operating cash flows, and ROE improvement towards 8-10% over the next two quarters, the hold stance can be maintained. However, any further deterioration in these metrics should trigger an exit. The lack of institutional interest and technical weakness suggest limited near-term upside.
Fair Value Estimate: ₹145-160 (15% downside risk from current levels), based on normalised earnings and peer P/E multiples of 35-40x applied to sustainable EPS of ₹4-4.50.
Note- ROCE= (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions.
